Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Montes

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
HIV Medicine|March 25, 2026
Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapyM D M Arcos-Rueda, R De Miguel-Buckley, A De Gea Grela, et al.
Journal of Viral Hepatitis|September 8, 2009
Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markersM Sánchez-Conde, M L Montes-Ramírez, P Miralles, et al.
The Journal of Antimicrobial Chemotherapy|April 14, 2009
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patientsJ Berenguer, J González-García, J López-Aldeguer, et al.
Revista De Neurologia|January 29, 2011
[HIV-1 neuropathogenesis: therapeutic strategies against neuronal loss induced by gp120/Tat glycoprotein in the central nervous system]J J Merino, M L Montes, A Blanco, et al.
HIV Medicine|May 17, 2023
Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world studyE Palmier, R De Miguel, R Montejano, et al.
HIV Medicine|April 5, 2023
Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119R Palacios, C Gómez-Ayerbe, J L Casado, et al.
Open Forum Infectious Diseases|July 25, 2022
Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral RegimensC Busca, M Sánchez-Conde, M Rico, et al.
Journal of Viral Hepatitis|December 7, 2010
Impact of liver steatosis on the correlation between liver stiffness and fibrosis measured by transient elastography in patients coinfected with human immunodeficiency virus and hepatitis C virusM Sánchez-Conde, M L Montes Ramírez, J M Bellón Cano, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 6, 2016
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV StudyM Laguno, M A Von Wichmann, E Van den Eynde, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
HIV Medicine|March 25, 2026
Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapyM D M Arcos-Rueda, R De Miguel-Buckley, A De Gea Grela, et al.
Journal of Viral Hepatitis|September 8, 2009
Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markersM Sánchez-Conde, M L Montes-Ramírez, P Miralles, et al.
The Journal of Antimicrobial Chemotherapy|April 14, 2009
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patientsJ Berenguer, J González-García, J López-Aldeguer, et al.
Revista De Neurologia|January 29, 2011
[HIV-1 neuropathogenesis: therapeutic strategies against neuronal loss induced by gp120/Tat glycoprotein in the central nervous system]J J Merino, M L Montes, A Blanco, et al.
HIV Medicine|May 17, 2023
Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world studyE Palmier, R De Miguel, R Montejano, et al.
HIV Medicine|April 5, 2023
Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119R Palacios, C Gómez-Ayerbe, J L Casado, et al.
Open Forum Infectious Diseases|July 25, 2022
Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral RegimensC Busca, M Sánchez-Conde, M Rico, et al.
Journal of Viral Hepatitis|December 7, 2010
Impact of liver steatosis on the correlation between liver stiffness and fibrosis measured by transient elastography in patients coinfected with human immunodeficiency virus and hepatitis C virusM Sánchez-Conde, M L Montes Ramírez, J M Bellón Cano, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 6, 2016
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV StudyM Laguno, M A Von Wichmann, E Van den Eynde, et al.
Pageof 2